Biomedical subjects

Xi-Zhang Lin

Publications and source records attributed to Xi-Zhang Lin.

4 recordsLinked to original sources

PubMedDate not supplied

Texture feature coding method for classification of liver sonography.

This paper introduces a new texture analysis method called texture feature coding method (TFCM) for classification of ultrasonic liver images. The TFCM transforms a gray-level image into a feature image in which each pixel is represented by a texture feature number (TFN) coded by TFCM. The TFNs obtained are used to generate a TFN histogram and a TFN co-occurrence matrix (CM), which produces texture feature descriptors for classification. Four conventional texture analysis methods that are gray-level CM, texture spectrum, statistical feature matrix and fractal dimension, are used also to classify liver sonography for comparison. The supervised maximum likelihood (ML) classifiers implemented by different type texture features are applied to discriminate ultrasonic liver images into three disease states that are normal liver, liver hepatitis and cirrhosis. The 30 liver sample images proven by needle biopsy are used to train the ML system that classify on a set of 90 test sample images. Experimental results show that the ML classifier together with TFCM texture features outperforms one with the four conventional methods with respect to classification accuracy.

Fractals↗

PubMedDate not supplied

Computed tomography demonstration of immediate and delayed complications of computed tomography-guided transthoracic percutaneous ethanol injection of hepatocellular carcinoma at the liver dome.

OBJECTIVE: We conducted this study to correlate computed tomography (CT) images with the complications induced by CT-guided percutaneous ethanol injection (PEI) for the treatment of hepatocellular carcinoma (HCC). METHODS: Twenty-two patients with ultrasonographically unreachable HCC were treated with CT-guided transthoracic PEI. The procedures and the CT findings were recorded to correlate with the various complications of PEI. RESULTS: After the ethanol injection, 3 patterns of CT images were identified according to the distribution of ethanol (ie, intratumoral, extrahepatic, and intrahepatic patterns). The intrahepatic pattern was further classified as the branch, tubular, and infiltrative types. During the follow-up period, 3 patients developed biliary stricture, portal vein thrombosis, or tumor seeding. The tubular type was associated with the development of biliary stricture, whereas the branch type was related to the occurrence of portal vein thrombosis. These complications were considered to be caused by a greater amount of ethanol leakage into bile ducts or portal veins than in cases without complications (median = 17 mL vs. 0 mL, P = 0.002). CONCLUSIONS: Ethanol leakage is not uncommon when performing PEI; however, it seems to be safe when the leakage is less than 15 mL. Injection of a small amount of ethanol or monitoring by CT may be helpful in preventing the development of these complications.

Administration, Cutaneous↗

PubMedDate not supplied

The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.

BACKGROUND/AIMS: This study was conducted to assess the clinical value of biliary CA 19-9, CA 125 and CEA sampled in different situations for the diagnosis of cholangiocarcinoma. METHODOLOGY: Bile was obtained from patients with bile duct obstruction on the day of biliary drainage and 3 days later separately. The etiology of biliary obstruction included choledocholithiasis (N = 51), hepatolithiasis (N = 19) and cholangiocarcinoma (N = 28). Patients of the former two conditions were all complicated with cholangitis. RESULTS: The sensitivity of biliary CEA, CA 19-9 and CA 125, whenever checked were all less than 70%. The biliary CEA and CA 19-9 were elevated in the presence of cholangitis. In addition, the biliary CEA was also increased in the patients with hepatolithiasis. The specificity of CA 125 was better than those of CEA and CA 19-9 (75.7% vs. 33.3% and 60%, respectively) on the day of biliary drainage. The diagnostic efficiency was slightly improved when combining biliary CA 125 and CEA. CONCLUSIONS: As the biliary CA 125 was less affected by inflammation and hepatolithiasis, it is more useful than CEA and CA 19-9 in the diagnosis of cholangiocarcinoma. The single tumor marker test of CA 125 or combined tumor marker test of CEA and CA 125 may be used as a useful complement to other investigative methods to differentiate benign from malignant causes of the bile duct obstruction.

Aged↗

PubMedDate not supplied

The value of biliary fibronectin for diagnosis of cholangiocarcinoma.

BACKGROUND/AIMS: The fibronectin in various body fluids was reported to be useful in the differential diagnosis of benign and malignant diseases. We conducted this study to assess the diagnostic value of biliary fibronectin. METHODOLOGY: Bile was collected from patients with gallstones (n = 62), benign biliary stricture (n = 5) and cholangiocarcinoma (n = 28). All patients with gallstones were complicated with cholangitis. The absolute biliary level of fibronectin was determined by an immunoenzymatric assay and divided by the biliary concentration of bile acids to calculate the relative concentration. RESULTS: The relative concentration of biliary fibronectin was significantly different among the patients with benign biliary obstruction, gallstone and cholangiocarcinoma (7.1 +/- 14.3 vs. 350.5 +/- 1535.4 vs. 180592.6 +/- 917236.2, p < 0.05). With a cut-off value of 40 ng/mumol, its sensitivity for diagnosing cholangiocarcinoma was 0.57, and specificity, 0.79. CONCLUSIONS: As bile may be concentrated or diluted to a various extent after biliary obstruction, the relative concentration of biliary fibronectin is more useful than the absolute concentration in differentiating the causes of biliary obstruction. In addition to the presence of biliary cancer, biliary fibronectin was also increased in response to biliary inflammation, which limits its use as a tumor marker of cholangiocarcinoma.

Aged↗